Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Krystal Biotech Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, which means each examiner is responsible for one pending matter. The portfolio is spread across 3 distinct art units, suggesting that the company's applications cover several different technical classifications within the biotech field. This distribution indicates a moderately diverse set of innovations currently undergoing review.
WILSON, MICHAEL C is the busiest examiner for the portfolio, currently holding 1 pending office action. Since there are 4 pending office actions and 4 distinct examiners, the workload is evenly split among the assigned staff. The use of 3 distinct art units indicates that while the technology area is consistent, the specific subject matter is varied enough to require review by multiple administrative groups. This profile shows an active prosecution phase with a balanced distribution of cases across 4 distinct examiners and 3 distinct art units, requiring the company to navigate different examiner preferences across multiple units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17255383 | COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY | BUTTICE, AUDREY L | 29d |
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | KELLY, ROBERT M | 44d overdue |
| 17255383 | COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY | BUTTICE, AUDREY L | 29d |
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | — |
| 18634382 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1638 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18896155 | Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic Applications | WILSON, MICHAEL C | — | §103§112Other | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18634382 | Methods and Compositions for Treating Conditions Involving the Eye | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Apr 12, 2024 |
| 18187884 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | 44d overdue | Pending | Mar 22, 2023 |
| 17255383 | COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY | BUTTICE, AUDREY L | 1647 | §103§112Other | Final Rejection | 29d | Pending | Jul 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial